Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 7/20 | 0.33 |
| ▸ | GBA1 | P04062 | 2/20 | 0.32 |
| ▸ | GBA2 | Q9HCG7 | 7/20 | 0.32 |
| ▸ | UGCG | Q16739 | 3/20 | 0.32 |
| ▸ | SI | P14410 | 2/20 | 0.32 |
| ▸ | AGL | P35573 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18608759 | 1.00 | MGAM (0.44) | MGAMGAAGBA1GBA2UGCG | |
| SCHEMBL25478397 | 0.77 | — | — | |
| SCHEMBL18608155 | 0.74 | — | — | |
| SCHEMBL11572899 | 0.68 | — | — | |
| SCHEMBL15593200 | 0.64 | MGAM (0.94) | MGAMGAAGBA1GBA2UGCG | |
| SCHEMBL19557626 | 0.64 | MGAM (0.94) | MGAMGAAGBA1GBA2UGCG | |
| SCHEMBL2431527 | 0.64 | MGAM (0.94) | MGAMGAAGBA1GBA2UGCG | |
| SCHEMBL16612897 | 0.64 | GBA1 (0.35) | MGAMGAAGBA1GBA2UGCG | |
| SCHEMBL22298937 | 0.62 | MGAM (0.43) | MGAMGAAGBA1 | |
| SCHEMBL2439599 | 0.62 | MGAM (1.00) | MGAMGAAGBA1GBA2UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186591-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | UNIVERSITÄT BASEL (CH) | 2021-11-30 | — | — | US | disclosed |
| US-20200277304-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277304-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIK3CA, MTOR, PIKFYVE | MGAM 4329/4885GAA 1324/4885GBA1 2025/4885 |
| US-11186591-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIK3CA, MTOR, PIKFYVE | MGAM 4329/4885GAA 1324/4885GBA1 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.